Abstract
Background: Unequal access to strong opioids remains an important challenge in resource-constrained healthcare settings. The distinctive feature of this case is the time-linked documentation of a physician request for fentanyl, an electronic prescribing record showing zero available fentanyl stock, an approximately 119.5-hour interval before fentanyl initiation, and serial pain assessments during that period. This report describes these medication-access events within a broader pain-management and medication-safety pathway in a patient with suspected advanced malignancy. Case Presentation: A 37-year-old woman was admitted to an island-based secondary hospital in Indonesia with abdominal enlargement, weakness, nausea and vomiting, poor appetite, and abdominal pain radiating to the lower back. Noncontrast computed tomography showed marked irregular hepatomegaly with innumerable hepatic nodules and massive ascites. Breast skin and nipple abnormalities were also present, but the primary malignancy was not pathologically confirmed. Pain was recorded as NRS 4/10 on admission, 5/10 on Day 2, 6/10 on Day 3, 7/10 on Day 4, and 9/10 from Day 5 through the pre-fentanyl assessment on Day 8. Ketorolac was administered at a regimen corresponding to up to 180 mg/day in a 35-kg patient over approximately 8– 9 days. Clobazam 10 mg daily was given for insomnia/restlessness for five doses. On Day 3, fentanyl was first requested when the NRS was 6/10; during the prescribing attempt, the hospital’s electronic prescribing interface showed zero available fentanyl stock. Pharmacy staff subsequently reported that other strong opioids were also unavailable, although this could not be independently verified from complete stock records. Fentanyl was initiated approximately 119.5 hours after the request at approximately 8.4 micrograms/hour without a loading dose or bolus. No rescue-opioid order or subsequent dose titration was documented during the following approximately 10.5 hours. The first post-initiation NRS reassessment was 5/10 at 21 minutes; this short observation cannot be confidently attributed to fentanyl. Hemodynamic instability and vasoactive support preceded fentanyl initiation. The patient subsequently deteriorated and died on Day 9 during comfort-focused intensive care. Conclusion: This case documents a prolonged interruption in access to a requested strong opioid during escalating severe pain, together with broader limitations in the pain-management pathway. The temporal record does not establish that the stockout caused clinical deterioration or death, nor that fentanyl produced the early change in pain score. The episode identifies medication-access continuity, therapeutic alternatives, opioid prescribing and titration, access to pain or palliative-care expertise, and medication safety as areas for local system review.